| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-04-30 | Clavis Pharma (Norway) Ventana Medical Systems (USA) |
hENT1 antibody to be used in companion diagnostic for Clavis Pharma's drug candidate CP-4126 and the hybridoma cell line that produces the antibody. / pancreatic cancer |
licensing |
See details |
| 2010-04-30 | CEVEC Pharmaceuticals (Germany) Aragen Bioscience (USA) |
recombinant human cell lines expressing biotherapeutic proteins and antibodies | licensing |
See details |
| 2010-04-29 | ARTES Biotechnology (Germany) Q Chip (UK) |
sustained release formulations of interferon alpha 2a these formulations will use Q Chip’s bioencapsulation technologies. / chronic hepatitis B and C |
development other |
See details |
| 2010-04-29 | Bicycle Therapeutics (UK) EPFL (Switzerland) |
bicyclic peptides | licensing other |
See details |
| 2010-04-29 | Galapagos (Belgium) CHDI Foundation (USA) |
/ Huntington's disease | R&D |
See details |
| 2010-04-28 | ProBioGen (Germany) Virdante Biopharmaceuticals (USA) |
cell line development and process engineering services for therapeutic proteins. / autoimmune and inflammatory diseases | manufacturing other |
See details |
| 2010-04-28 | Pepscan (The Netherlands) Immunovo |
therapeutic vaccine portfolio that includes an anti-VEGF-A vaccine that could be useful for the treatment of certain cancers. |
licensing development other |
See details |
| 2010-04-27 | Ipsen (France) Invida (Singapore) |
Diphereline®/Decapeptyl®, Somatuline® Autogel® and Increlex® | commercialization/ distribution marketing/ promotion |
See details |
| 2010-04-27 | PolyTherics (UK) undisclosed pharmaceutical company |
proprietary drug modification technologies to a target protein | R&D other |
See details |
| 2010-04-27 | Cellectis (France) VIB (Belgium) |
/ haemophilia | R&D |
See details |
| 2010-04-23 | Clavis Pharma (Norway) Clovis Oncology (USA) Ventana Medical Systems (USA) |
hENT1 companion diagnostic to CP-4126 (lipid-conjugated form of the anti-cancer drug gemcitabine) / pancreatic cancer | development |
See details |
| 2010-04-16 | 4SC (Germany) Nexigen (Germany) |
/ cancer | R&D development |
See details |
| 2010-04-15 | Swedish Orphan Biovitrum (Sweden) Pharming Group (The Netherlands) |
Rhucin® (conestat alfa - recombinant human C1 inhibitor) / Hereditary angioedema |
commercialization/ distribution |
See details |
| 2010-04-13 | Mersana Therapeutics (USA) Teva Pharmaceuticals (Israel) |
XMT-1107 is a conjugate of a novel analog of fumagillin (angiogenesis inhibitor) and Fleximer® (biodegradable and bio-inert polymer that can be chemically linked to small molecules, biologics and nucleic acids to enhance their pharmacokinetic and safety profiles). / cancer and other potential indications |
R&D licensing |
See details |
| 2010-04-12 | Proximagen Neuroscience (UK) Upsher-Smith (USA) |
tonabersat / epilepsy | licensing commercialization/ distribution development marketing/ promotion |
See details |
